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In the past 70 years, epidemiology has gone through a
substantial development of both methodology and more
sophisticated analyses with determinant- and disease-
specific elements. Despite the discussion earlier in this
journal as to whether the duality of epidemiology’s
embrace of both research methods and content-based topics
is a positive development [1, 2], it shows at least that
epidemiology as a discipline is able to re-invent itself and
to adapt to the rapid scientific evolution which currently
takes place. Whereas the methodological ‘toolkit’ keeps its
solid basis in cohort- and case-control designs, determi-
nant-oriented genetic epidemiology and pharmacoepi-
demiology, and disease-oriented cardiovascular and
infectious diseases epidemiology are examples of branch-
ing within one discipline. While the start of epidemiology
had its main focus on hypothesis-testing concerning the
association between determinants and disease as well as
risk estimation, the importance of hypothesis-generating
studies is increasing. A nice example is the technique of
genome-wide association studies which led to an explosion
of discoveries in genetic epidemiology, also by a new
model of collaborative science [3]. However, genes remain
while drugs come and disappear again from human society.
This makes pharmacoepidemiology an important hypoth-
esis-generating and -testing vacuum cleaner of the phar-
maceutical market. Elsewhere in this journal, Chia-Cheng
Lai et al. [4] reviewed ‘sequence symmetry analysis’ as a
technique for detecting adverse drug events by utilizing
computerized claims data. Data mining techniques such as
this one are considered of increasing importance. There are
two reasons for that development. First, the enormous
expansion of information technology in the past 30 years
facilitated the easy access to huge amounts of healthcare
information. In the stone age of pharmacovigilance and
pharmacoepidemiology, a new adverse reaction not dis-
covered in clinical trials was usually reported in the first
years of marketing by intelligent medical observers with an
open eye for new and unexpected events in their patients
[5]. The more relevant of these reports were actively
published in medical journals as ‘short reports’ or ‘letters
to the editor’. The most serious ones were occasionally
investigated in relatively small hospital-based cohort
studies or population-based case-control studies with the
aim to confirm signals from adverse event reports and
calculate the magnitude of a risk increase. Such studies
were expensive and time-consuming because data had to be
collected and collated de novo. Nowadays, expensive
multi-center studies on adverse reactions to drugs such as
the International Agranulocytosis and Aplastic Anemia
Study [6] and the International Primary Pulmonary
Hypertension Study Group [7] would probably no longer
be performed in that way. The more and more easy access
to healthcare information in databases in most developed
countries in the world is too efficient to omit. Second, there
is the growing risk aversion in Western countries and fear
for litigation. Consequently, increasingly strict legislation
for obtaining a marketing authorization by regulatory
authorities such as the FDA and the European Medicines
Agency EMA have forced the pharmaceutical industry to
demonstrate their active surveillance of literature, and
signal generating activities. How far these requirements go,
can be read in EMA guidelines for signal management [8].
Also, jurisdiction regarding adverse reactions in the past,
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especially in the U.S.A., demonstrates the important con-
sequences of inadequate adverse reaction management [9].
Is this all good news? After all, everybody will recog-
nize the importance of early detection of adverse reactions
and use of healthcare information which is already avail-
able. However, we should not lose sight of the other side of
the coin. Datamining of healthcare data generates many
false-positive signals which have to be checked because the
strict legislation and jurisdiction on adverse events, negli-
gence and medical errors [10], in combination with risk
aversion might force society to investigate every signal.
Unfortunately, the efficiency of datamining is probably
much lower than reporting of adverse events by intelligent
observers [11] and will drain resources from important
hypothesis-testing research with higher a priori chances of
confirmation. As for hypothesis-testing, one might question
whether the abundant availability of automated healthcare
information will lead to a decline of the number of de novo
epidemiological field studies in pharmacoepidemiology.
This would be a loss because healthcare information may
be very prone to selection and information bias while every
studied intervention will suffer from confounding by
indication. Information in such databases is healthcare-
driven and determinants are not gathered for everyone and
in the same way for all members of a population. For
instance, potential confounders such as smoking or BMI
are often not registered. Nevertheless, there is a strong
tendency to use such information by health care insurance
companies and other health care bodies for guidelines and
pharmaco-economic modeling. Increasing employment of
healthcare databases for post-authorization studies is too
efficient to discourage but the potential misclassification of
disease and co-factors should not be taken too lightly and
lead to a card house of facts mixed with fictions. Big data
are as attractive as nuclear energy to some of us. Keeping
validity on board seems to me as being a greater challenge
than dualities within our discipline.
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